HIV science has made remarkable progress. While we still lack a vaccine or cure, a single dose of a new long-acting injectable drug can now offer protection against HIV for up to six months . This ...

The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in ...

Africa is contributing to this growth as the need for advanced wireless networks continues to rise. According to Telecom testing solutions provider Simnovus, Open RAN architecture not only simplifies ...

1 Day TRIB 0.67% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

MedMira Inc. (MedMira) announced that it has received the approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) for Point-of-Care (POC) use. The Reveal HIV rapid test has ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills in a case that raised questions about the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Individuals’ fear about knowing their HIV status and testing for it are factors that delay people coming forward, says Lyons. “HIV is just another condition that can be managed and that anyone ...